1. Garg PK, Perry S, Dorn M, et al. Risk of intestinal helminth and protozoan infection in a refugee population. Am J Trop Med Hyg 2005;73:386-391.

2. White AC, Atmar RL. Infections in Hispanic immigrants. Clin Infect Dis 2002;34:1627-1632.

3. Bledsoe GH. Malaria primer for clinicians in the United States. South Med J 2005;98:1197-1204.

4. Chen LH, Wilson ME, Schlagenhauf P. Controversies and misconceptions in malaria chemoprophylaxis for travelers. JAMA 2007;297:2251-2263.

5. Malaria Surveillanceā€”United States, 2007. MMWR Surveill Summ 2009;58(SS-02):1-16.

6. Vicas AE, Albrecht H, Lennox JL, del Rio C. Imported malaria at an inner-city hospital in the United States. Am J Med 2005;329:6-12.

7. Franco-Paredes C, Santos-Preciado JI. Problem pathogens: Prevention of malaria in travelers. Lancet Infect Dis 2006;6:139-149.

8. Nuesch R, Zimmerli L, Stockli R, et al. Imported Strongyloidosis: A longitudinal analysis of 31 cases. J Travel Med 2005;29:80-84.

9. John DT, Petri WA Jr. Markell and Voge's Medical Parasitology, 9th ed. Philadelphia: Saunders, 2006.

10. Escobedo AA, Cimerman S. Giardiasis: A pharmacotherapy review. Expert Opin Pharmacother 2007;8(12):1885-1902.

11. Hill DR. Giardia lamblia. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and Practice of Infectious Diseases, 7th ed. New York: Elsevier Churchill-Livingstone, 2009:3527-3534.

12. Drugs for parasitic infections. In: Handbook of Antimicrobial Therapy, 18th ed. New Rochelle, NY: Medical Letter, 2008:225-280.

13. Lebwohl B, Deckelbaum RJ, Green PHR. Giardiasis. Gastrointest Endosc 2003;57:906-913.

14. Huang DB, White AC. An updated review on Cryptosporium and Giardia. Gastroenterol Clin North Am 2006;35:291-314.

15. Sorell L, Garrote JA, Galvan JA, et al. Celiac disease diagnosis in patients with giardiasis: High value of antitransglutaminase antibodies. Am J Gastroenterol 2004;99:1330-1332.

16. Nitazoxanide (alina): A new antiprotozoal agent. Med Lett Drugs Ther 2003;45:29-31.

17. Hung C-C, Deng H-Y, Hsiao W-H, et al. Invasive amebiasis as an emerging parasite disease in patients with human immunodeficiency virus type 1 infection in Taiwan. JAMA 2005;165:409-415.

18. Farthing MJG. Intestinal protozoa. Entamoeba histolytica. In: Manson's Tropical Diseases, 22nd ed. London: WB Saunders, 2009: 1375-1386.

19. Haque R, Huston CD, Hughes M, et al. Amebiasis. N Engl J Med 2003;348:1565-1573.

20. Petri Jr WA, Haque R. Entamoeba histolytica (amebiasis). In: Mandell GL, Bennett JA, Dolin R, eds. Principles and Practice of Infectious Diseases, 7th ed. New York: Elsevier Churchill-Livingstone, 2009:3411-3425.

21. Salles JM, Morales LA, Salles MC. Hepatic Amebiasis. Braz J Infect Dis 2003;7:96-110.

22. Bercu TE, Petri Jr WA, Behm BW. Amebic colitis: New insights into pathogenesis and treatment. Curr Gastroenterol Rep 2007;9:429-433.

23. Ozdogan M, Baykal A, Aran O. Amebic perforation of the colon: Rare and frequently fatal complication. World J Surg 2004;28:926-929.

24. Maguire JH. Intestinal nematodes (roundworms). In: Mandell GL, Bennett JE, Dolin R, eds. Principles and Practice of Infectious Diseases, 7th ed. New York: Elsevier Churchill-Livingstone, 2009:3577-3586.

25. Bethony J, Brooker S, Albonico M, et al. Soil-transmitted helminth infection: Ascariasis, trichuriasis, and hookworm. Lancet 2006;367: 1521-1532.

26. Hotez PJ, Brooker S, Bethony JM, et al. Hookworm infection. N Engl J Med 2004;357:799-807.

27. Gabriella AF, Ramsan M, Naumann C, et al. Soil-transmitted helminthes and haemoglobin status among Afghan children in World Food Programme Assisted Schools. J Helminthol 2005;79:381-384.

28. Larocque R, Casapia M, Gotuzzo E, Gyorkos TW. Relationship between intensity of soil-transmitted helminth infections and anemia in pregnancy. Am J Trop Med Hyg 2005;73:783-789.

29. Sahoo PK, Satapathy AK, Michael E, Ravindran B. Concomitant parasitism: Ban-croftian Filariasis and intestinal helminthes and response to albendazole. Am J Trop Med Hyg 2005;73:877-880.

30. Malik AH, Saima BD, Wani MY. Management of hepatobiliary and pancreatic as-cariasis in children of endemic area. Pediatr Surg Int 2006;22:164-168.

31. Huratado RM, Sahani DV, Kradin RL. Case records of the Massachusetts General Hospital. Case 9-2006. A 35-year-old woman with recurrent-upper-quadrant pain. N Engl J Med 2006;354:1295-1303.

32. Petro M, Iavu K, Minocha A. Unusual endoscopic and microscopic view of En-terobius vermicularis: A case report with review of the literature. South Med J 2005;98:927-929.

33. Keiser PB, Nutman TB. Strongyloides stercoralis in the immuno-compromised population. Clin Microbiol Rev 2004;17:208-217.

34. Lim S, Katz K, Krajden S, et al. Complicated and fatal Strongyloides infection in Canadians: Risk factors, diagnosis and management. Can Med Assoc J 2004;171:479-484.

35. Schaeffer MW, Buell JF, Gupta M, et al. Strongyloides hyperinfection syndrome after heart transplantation: Case report and review of literature. J Heart Lung Transplant 2004;23:905-911.

36. Concho R, Harrington W, Rogers AI. Intestinal Strongyloidiasis: Recognition, management, and determinants of outcome. Clin Gastroenterol 2005;39:203-211.

37. Newberry AM, Williams DN, Stauffer WM, et al. Strongyloides hyperinfection presenting as acute respiratory failure and gram-negative sepsis. Chest 2005;128:3681-3684.

38. Satoh M, Kokaze A. Treatment strategies in controlling strongyloidiasis. Expert Opin Pharmacother 2004;5:2293-2301.

39. Muennig P, Pallin D, Challah C, Khan K. The cost-effectiveness of ivermectin vs albendazole in the presumptive treatment of strongyloidiasis in immigrants to the United States. Epidemiol Infect 2004;132:1055-1063.

40. King CH. Cestodes (tapeworms). In: Mandell GL, Dolin R, Bennett JE, eds. Principles and Practice of Infectious Diseases, 7th ed. New York: Elsevier Churchill-Livingstone, 2009:3607-3616.

41. Garcia HH, Gonzalez AE, Evans CAW, Gilman RH. Taenia solium cysticercosis. Lancet 2003;361:547-556.

42. Del La Garza Y, Graviss EA, Daver NG, et al. Epidemiology of neurocysticercosis in Houston, Texas. Am J Trop Med Hyg 2005;73:766-770.

43. Townes JM, Hoffmann CJ, Kohn MA. Neurocysticercosis in Oregon, 1995-2000. Emerging Infect Dis 2004;10:508-510.

44. Dua T, Aneja S. Neurocysticercosis: Management issues. Indian Pediatr 2006;43:227-235.

Garcia HH, Del Brutto OH, Nash TE, et al. New concepts in the diagnosis and management of neurocysticercosis (Taenia solium). Am J Trop Med Hyg 2005;72:3-9.

Gongora-Rivera F, Soto-Hernandez JL, Esquivel DG, et al. Albendazole trial at 15 or 30 mg/kg/day for subarachnoid and intraventricular cysticercosis. Neurology 2006;66:436-438.

Fairhurst RM, Wellems TE. Plasmodium species (malaria). In: Mandell GL, Dolin R, Bennett JE, eds. Principles and Practice of Infectious Diseases, 7th ed. New York: Elsevier Churchill-Livingstone, 2009:3437-3462.

White NJ, Breman JG. Malaria and babesiosis: Diseases caused by red blood cell parasites. In: Harrison's Principles of Internal Medicine, 18th ed. New York: McGraw-Hill, 2008:1280-1294.

Newman RD, Parise ME, Barber AM, Steketee RW. Malaria-related deaths among travelers, 1963-2001. Ann Intern Med 2004;141:547-555.

Kitchen AD, Chiodini PL. Malaria and blood transfusion. Vox Sang 2006;90:77-84.

White NJ. Malaria. In: Cook GC and Zumla A, eds. Manson's Tropical Diseases, 21st ed. London: WB Saunders, 2003:1205-1295.

Idro R, Carter JA, Fegan G, et al. Risk factors for persisting neurological and cognitive impairment following cerebral malaria. Arch Dis Child 2006;91:142-148.

Idro R, Jenkins NE, Newton CRJC. Pathogenesis, clinical features, and neurological outcome of cerebral malaria. Lancet Neurol 2005;4:827-840.

Pasvol G. Management of severe malaria: Interventions and controversies. Infect Dis Clin North Am 2005;19:211-240.

Eiam-Ong S. Malarial nephropathy. Semin Nephrol 2003;23:21-33.

Trampuz A, Jereb M, Muzlovic I, Prabhu RM. Clinical Review: Severe Malaria. Crit Care 2003;7:315-323.

Riddle MS, Jackson JL, Sanders JW, Blazes DL. Exchange transfusion as an adjunct therapy in severe Plasmodium falciparum malaria: A meta-analysis. Clin Infect Dis 2002;34:1192-1198.

Taylor WRJ, White NJ. Malaria and the lung. Clin Chest Med 2002;23:457-468.

Singh N, Saxena A. Usefulness of a rapid on-site plasmodium falciparum diagnosis (PARACHECKĀ® PF) in forest migrants and among the indigenous population at the site of their occupational activities in central India. Am J Trop Med Hyg 2005;72:26-29.

60. Magill AJ. The prevention of malaria. Prim Care 2002;29:815-842.

61. Chen LH, Wilson ME, Schlagenhauf P. Prevention of malaria in long-term travelers. JAMA 2006;296:2234-2244.

62. Shanks GD, Edstein MD. Modern malaria chemoprophylaxis. Drugs 2005;65:2091-2110.

63. Taylor WRJ, White NJ. Antimalarial drug toxicity. Drug Saf 2004;27:25-61.

64. Tako EA, Zhou A, Lohoue J, et al. Risk factors for placental malaria and its effect on pregnancy outcome in Yaounde, Cameroon. Am J Trop Med Hyg 2005;72:236-242.

65. Sharma S, Pathak S. Malaria vaccine: A current perspective. J Vector Borne Dis 2008;45:1-20.

66. Ballou WR, Arevalo-Herrera M, Carucci D, et al. Update on the clinical development of candidate malaria vaccines. Am J Trop Med Hyg 2004;71:239-247.

67. Alonso P, Sacarlal J, Aponte JJ, et al. Efficacy of the RTS, S/ASO2A vaccine against Plasmodium infection and disease in young African children: Randomized controlled trial. Lancet 2004;364:1411-1420.

68. Bacaner N, Stauffer B, Boulware DR, Walker PF, Keystone JS. Travel medicine considerations for North American immigrants visiting friends and relatives. JAMA 2004;291:2856-2864.

69. Rathore D, McCutchan TF, Sullivan M, Kumar S. Antimalarial drugs: Current status and new developments. Expert Opin Investig Drugs 2006;14:871-883.

70. Chen LH, Keystone JS. New strategies for the prevention of malaria in travelers. Infect Dis Clin North Am 2005;19:185-210.

71. Rosenthal PJ. Artesunate for the treatment of severe Falciparum malaria. N Engl J Med 2008;358:1829-1836.

72. Price RN, Uhlemann A-C, van Vugt M, et al. Molecular and pharmacological determinants of the therapeutic response to artemether-lumefantrine in multi-resistant Plasmodium falciparum malaria. Clin Infect Dis 2006;42:1570-1577.

73. Fradin MS, Day JF. Comparative efficacy of insect repellents against mosquito bites. N Engl J Med 2002;347:13-18.

74. Rosenthal PJ. Antiprotozoal drugs. In: Katzung BG, ed. Basic and Clinical Pharmacology, 11th ed. New York: Lange Medical Books/McGraw-Hill, 2009:899-921.

75. Barrett MP, Burchmore RJS, Stich A, et al. The trypanosomiasis. Lancet 2003;362:1469-1480.

76. Marin-Neto JA, Cunha-Neto E, Maciel BC, Simoes MV. Pathogenesis of chronic Chagas heart disease. Circulation 2007;115:1109-1123.

77. Kirchhoff LV. Trypanosoma species (American trypanosomiasis, Chagas' disease): Biology of trypanosomes. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and Practice of Infectious Diseases, 7th ed. New York: Elsevier Churchill-Livingstone, 2009:3481-3488.

78. Kirchhoff LV. American trypanosomiasis (Chagas disease). In: Guerrant RL, Walker H, WellerPF, eds. Tropical Infectious Diseases: Principles, Pathogens, and Practice, 2nd ed. 2006:1082-1094.

79. Carod-Artal FJ, Vargas AP, Melo M, Horan TA. American trypanosomiasis (Chagas' disease): An unrecognized cause of stroke. J Neurol Neurosurg Psychiatry 2003;74:516-518.

80. Schijman AG, Vigliano CA, Viotti RJ, et al. Trypanosoma cruzi DNA in cardiac lesions of Argentine patients with end-stage chronic Chagas heart disease. Am J Trop Med Hyg 2004;70:210-220.

81. Chagas disease after organ transplantation - Los Angeles, California, 2006. MMWR Morb Mortal Wkly Rep 2006;55:798-800.

82. Viotti R, Vigliano C, Lococo B, et al. Long-term cardiac outcomes of treating chronic Chagas disease with benznidazole versus no treatment. A nonrandomized trial. Ann Intern Med 2006;144:724-734.

83. Rosenthal PJ. Clinical pharmacology of the anthelmintic drugs. In: Katzung BG, ed. Basic and Clinical Pharmacology, 11th ed. New York: Lange Medical Books/ McGraw-Hill, 2009:923-934.

84. Diaz SH. Lice (pediculosis). In: Mandell GL, Bennett JR, Dolin R, eds. Principles and Practice of Infectious Diseases, 7th ed. New York: Elsevier Churchill-Livingstone, 2009:3629-3632.

85. Roberts RJ. Head lice. N Engl J Med 2002;346:1645-1650.

86. Yoon KS, Gao J-R, Taplin D, et al. Permethrin-resistant human head lice, pediculus capitis, and their treatment. Arch Dermatol 2003; 139:994-1000.

87. Burkhart CG. Relationship of treatment-resistant head lice to the safety and efficacy of pediculicides. Mayo Clin Proc 2004;79:661-666.

88. Jones KN, English III JC. Review of common therapeutic options in the United States for the treatment of pediculosis capitis. Clin Infect Dis 2003;36:1355-1361.

89. Johnson G, Sladden M. Scabies: Diagnosis and treatment. Br Med J 2005;331:619-622.

90. Chosidow O. Scabies. N Engl J Med 2006;354:1718-1727.

Anxiety and Depression 101

Anxiety and Depression 101

Everything you ever wanted to know about. We have been discussing depression and anxiety and how different information that is out on the market only seems to target one particular cure for these two common conditions that seem to walk hand in hand.

Get My Free Ebook

Post a comment